Boehringer Ingelheim began construction in December of 2017 on a 50,000-sf expansion of its 350,000-sf animal vaccine production facility in Athens, Ga. The completed 400,000-sf project will begin commercial operations in mid-2019. Boehringer Ingelheim will also construct a 13,000-sf addition for the manufacture of livestock animal vaccines on its 700,000-sf campus in St. Joseph, Mo.
PharmaForce is planning a $145 million expansion its Ohio pharmaceutical production facilities. A 140,000-sf addition will be constructed on the New Albany campus to accommodate increased manufacturing and warehousing operations, and existing production and warehouse space will be renovated. The Hilliard facility will be renovated and expanded by 1,800 sf to house new manufacturing equipment and supporting infrastructure. Construction will begin in 2018.
The University of Oregon broke ground in March of 2018 on the Phil and Penny Knight Campus for Accelerating Scientific Impact in Eugene. Designed by Ennead Architects and Bora Architects, the first phase of construction will include a $225 million, 160,000-sf facility providing interdisciplinary laboratories for biomedical research, collaboration areas, and public spaces. Completion is expected in early 2020.
Pfizer’s pharmaceutical factory in Dalian, China, has attained LEED-NC Platinum sustainable design certification. The project, which involved a 140,000-sf expansion to accommodate an aseptic workshop for cephalosporin products, began construction in 2014 and reached completion in April of 2017. As the chosen strategic partner for the project, Johnson Controls was involved throughout the design and construction process and provided building controls systems and lifecycle green building certification consulting services.
Mayo Clinic is partnering with United Therapeutics to build a $41 million lung restoration center in Jacksonville, Fla. Located on Mayo’s Southside campus, the three-story, 75,000-sf facility will support the optimization of lungs destined for transplantation, as well as providing offices, conference rooms, and biomedical research space. Whiting-Turner will begin construction on the project in late 2017 with occupancy expected in spring of 2019.
Hitachi Chemical Advanced Therapeutics Solutions is expanding its cell and gene therapy manufacturing operations in Allendale, N.J. The project includes construction of a 49,700-sf addition accommodating the Center for Innovation and Engineering, controlled environment rooms, and labs for microbiology, manufacturing development, and quality control. An existing 30,000-sf cleanroom production facility will also be renovated. Completion is expected in mid-2018.
MilliporeSigma opened its 280,000-sf Life Sciences Center in October of 2017 in Burlington, Mass. Accommodating approximately 100 employees, the facility provides offices and a collaboration center for customers to engage in training, troubleshooting, and experimentation activities. Additionally, a biodevelopment lab enabling small-scale pharmaceutical manufacturers to conduct early-stage clinical trials will open at the site by January of 2018. The Life Sciences Center is located in a five-story leased facility and represents an investment of $115 million.
Cold Spring Harbor Laboratory broke ground in October of 2017 on the $75 million Center for Therapeutics Research in Cold Spring Harbor, N.Y. The project includes renovation of the existing Demerec Lab to create a 26,000-sf facility accommodating collaborative research in biology, chemistry, and genomics. The center will support the development of treatments for cancer, diabetes, leukemia, autism, and obesity. Completion is expected in late 2018.
ADC Biotechnology is planning to build a 70,000-sf bioconjugation facility in Deeside in the United Kingdom. Featuring GMP production suites, the $11 million integrated facility will support the manufacture of antibody drug conjugates for all clinical phases as well as small-scale commercial production. The project will include space for R&D, process development, quality control, and warehousing. Operations will commence by December of 2018.
Sartorius Stedim Cellca is constructing a $35 million Cell Culture Technology Center in Ulm, Germany. Located at Science Park III in Eselsberg, the lab and office facility will support the development of cell culture and protein production technologies. Completion is expected in 2019.
Eli Lilly and Company embarked on a year-long process to create a new collaborative and flexible space model dubbed CoLAB. In order to achieve the flexibility they aim for, Lilly is employing the use of ceiling infrastructure and innovative fume hoods, the design of which ultimately saved hundreds of thousands of dollars. CoLAB’s purpose is to collocate previously separated groups into a new research campus, specifically stressing collaboration, innovation, and speed-to-market of new therapies. The initiative is designed to address constraints caused by both geographic separation and aging facilities in the Small Molecule Design and Development (SMDD) organization, the group that is responsible for the scale-up work that acts as the bridge between research and manufacturing.
Roche Diagnostics has leased research space in NB Development Group’s Boston Landing. Roche will take occupancy of the approximately 29,000-sf facility, which is located in a 246,405-sf structure at 80 Guest Street, in early 2018. Proteostasis Therapeutics will also occupy a similar footprint in the building in early 2018.
Ferring Pharmaceuticals is planning to construct a 124,000-sf headquarters and research facility in Copenhagen. Designed by Foster + Partners, the facility will provide collaborative biopharmaceutical labs and offices to support the development of innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology, and orthopedics. The building will include six stories above grade and two basement levels.
SAB Biotherapeutics began construction in August of 2017 on an agricultural production facility for antibody therapeutics. The 80-acre ‘pharm’ will accommodate transgenic cattle which produce plasma in reaction to a vaccine, providing a source of natural human polyclonal antibodies. The facility is located adjacent to SAB’s existing corporate headquarters and is slated for completion in spring of 2018.
The Institute of Cancer Research is planning to build a £70 million facility in Sutton, one of the southernmost boroughs of London. Accommodating multidisciplinary drug discovery research, the 75,000-sf project will house 275 investigators, including cancer biologists, evolutionary scientists, medicinal chemists, pharmacologists, data scientists, and clinicians. Occupancy is expected in mid-2020.
